AIDS: The final chapter?

AIDS Research and Human Retroviruses

Volumn 30, Issue 1, 2014, Pages 5-6

  Krim, Mathilde ^a   Johnston, Rowena ^a  

^a Foundation for AIDS Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; NOTE; PRIORITY JOURNAL; PROPHYLAXIS; UNITED STATES; EPIDEMIC; MEDICAL RESEARCH; PUBLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; BIOMEDICAL RESEARCH; EPIDEMICS; HUMANS; PERIODICALS AS TOPIC;

EID: 84891817348     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2013.1503     Document Type: Note

References (25)

1. De Clercq E: HIV inhibitors targeted at the reverse transcriptase. AIDS Res Hum Retroviruses 1992;8(2):119-134.
2. Debouck C: The HIV protease as a therapeutic target for AIDS. AIDS Res Hum Retroviruses 1992;8(2):153-164.
3. Wild C, Greenwell T, and Matthew T: A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum Retroviruses 1993;9(11): 1051-1053.
4. Young B, Squires KE, Ross LL, Santiago L, Sloan LM, Zhao HH, Wine BC, Pakes GE, Margolis DA, Shaefer MS, and the Aries EPZ108859 Study Team: Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/ lamivudine/atazanavir with or without ritonavir in ARIES. AIDS Res Hum Retroviruses 2013;29(2):350-358.
5. Jansen K, Sönnerborg A, Brockmeyer N, Thalme A, Svedhem V, Dupke S, Eychenne JL, Nakonz T, Jimenez-Exposito MJ, and Pugliese P: Long-term efficacy and safety of atazanavir/ritonavir treatment in a real-life cohort of treatment-experienced patients with HIV type 1 infection. AIDS Res Hum Retroviruses 2013;29(3):564-573.
6. Albini L, Calabresi A, Gotti D, Ferraresi A, Festa A, Donato F, Magoni M, Castelli F, and Quiros-Roldan E: Burden of non-AIDS-defining and non-virus-related cancers among HIV-infected patients in the combined antiretroviral therapy era. AIDS Res Hum Retroviruses 2013;29(8): 1097-1104.
7. Hsieh SM, Pan SC, Chang SY, Hung CC, Sheng WH, Chen MY, and Chang SC: Differential impact of resistanceassociated mutations to protease inhibitors and nonnucleoside reverse transcriptase inhibitors on HIV-1 replication capacity. AIDS Res Hum Retroviruses 2013;29(8): 1117-1122.
8. Reynes J, Trinh R, Pulido F, Soto-Malave R, Gathe J, Qaqish R, Tian M, Fredrick L, Podsadecki T, Norton M, and Nilius A: Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study. AIDS Res Hum Retroviruses 2013;29(2):256-265.
9. Hütter G, Nowak D, Mossner M, Ganepola S, Müssig A, Allers K, Schneider T, Hofmann J, Kücherer C, Blau O, Blau IW, Hofmann WK, and Thiel E: Long-term control of HIV by CCR5 delta32/delta32 stem-cell transplantation. N Engl J Med 2009;360(7):692-698.
10. Yukl SA, Boritz E, Busch M, Bentsen C, Chun TW, Douek D, Eisele E, Haase A, Ho YC, Hütter G, Justement JS, Keating S, Lee TH, Li P, Murray D, Palmer S, Pilcher C, Pillai S, Price RW, Rothenberger M, Schacker T, Siliciano J, Siliciano R, Sinclair E, Strain M, Wong J, Richman D, and Deeks SG: Challenges in detecting HIV persistence during potentially curative interventions: A study of the Berlin patient. PLoS Pathog 2013;9(5):e1003347.
11. Persaud D, Gay H, Ziemniak C, Chen YH, Piatak M Jr, Chun TW, Strain M, Richman D, and Luzuriaga K: Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med 2013;369(19):1828-1835.
12. Henrich T, Hanhauser E, Sirignano M, Davis B, Lee T-H, Keating S, Busch M, Marty F, LaCasce A, Armand P, Soiffer R, Altfeld M, and Kuritzkes D: In depth investigation of peripheral and gut HIV-1 reservoirs, HIV-specific cellular immunity, and host microchimerism following allogeneic hematopoetic stem cell transplantation. International AIDS Society conference, 2013, WELBA05.
13. Josefsson L, von Stockenstrom S, Faria NR, Sinclair E, Bacchetti P, Killian M, Epling L, Tan A, Ho T, Lemey P, Shao W, Hunt PW, Somsouk M, Wylie W, Douek DC, Loeb L, Custer J, Hoh R, Poole L, Deeks SG, Hecht F, and Palmer S: The HIV-1 reservoir in eight patients on longterm suppressive antiretroviral therapy is stable with few genetic changes over time. PNAS 2013;110(51):E4987- E4996.
14. Eriksson S, Graf EH, Dahl V, Strain MC, Yukl SA, Lysenko ES, Bosch RJ, Lai J, Chioma S, Emad F, Abdel-Mohsen M, Hoh R, Hecht F, Hunt P, Somsouk M, Wong J, Johnston R, Siliciano RF, Richman DD, O'Doherty U, Palmer S, Deeks SG, and Siliciano JD: Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog 2013;9(2):e1003174.
15. Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, Yang HC, Zhang H, Margolick JB, Blankson JN, and Siliciano RF: Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012;36(3):491-501.
16. Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DI, Lai J, Blankson JN, Siliciano JD, and Siliciano RF: Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 2013;155(3):540-551.
17. [No authors listed]: AIDS vaccine 2013 October 7-10, 2013 Barcelona, Spain. AIDS Res Hum Retroviruses 2013; 29(11):A1-A208.
18. Karasavvas N, Billings E, Rao M, Williams C, Zolla-Pazner S, Bailer RT, Koup RA, Madnote S, Arworn D, Shen X, Tomaras GD, Currier JR, Jiang M, Magaret C, Andrews C, Gottardo R, Gilbert P, Cardozo TJ, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Paris R, Greene K, Gao H, Gurunathan S, Tartaglia J, Sinangil F, Korber BT, Montefiori DC, Mascola JR, Robb ML, Haynes BF, Ngauy V, Michael NL, Kim JH, de Souza MS, and the MOPH TAVEG Collaboration. The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses 2012;28(11):1444-1457.
19. Klasse PJ, Sanders RW, Cerutti A, and Moore JP: How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development? AIDS Res Hum Retroviruses 2012;28(1):1-15.
20. Kiser PF, Mesquita PM, and Herold BC: A perspective on progress and gaps in HIV prevention science. AIDS Res Hum Retroviruses 2012;28(11):1373-1378.
21. National Institute of Allergy and Infectious Diseases, Workshop Summary: Scientific Evidence on Condom Effectiveness for Sexually Transmitted Disease (STD) Prevention, July 20, 2001.
22. Cohen J: Miracle on 34th Street: Success with injectors. Science 2012;337(6091):178-180.
23. Baeten JM, Haberer JE, Liu AY, and Sista N: Preexposure prophylaxis for HIV prevention: Where have we been and where are we going? J Acquir Immune Defic Syndr 2013; 63(Suppl 2):S122-129.
24. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al.: Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010;329:1168-1174.
25. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Mehendale S, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Wang L, Makhema J, Mills LA, de Bruyn G, Sanne I, Eron J, Gallant J, Havlir D, Swindells S, Ribaudo H, Elharrar V, Burns D, Taha TE, Nielsen-Saines K, Celentano D, Essex M, Fleming TR, and the HPTN 052 Study Team: Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365(6):493-505.